Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
New research from CU Cancer Center member Scott Cramer, PhD, and his colleagues could help in the treatment of men with certain aggressive types of prostate cancer.
A compound isolated from a fungus growing on the roots of a flowering plant in Morocco shows promise as a powerful opponent of aggressive triple negative breast cancer, scientists say.
Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy.
Researchers at the University of Bern led an international team that has identified a novel vulnerability in advanced prostate cancer that is no longer responding to hormonal therapy.
Results from the PROfound phase III study, funded by AstraZeneca and Merck Sharp & Dohme, open up a much-needed new treatment avenue for the more precise and effective treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed with hormonal therapy.
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
UC researchers and physicians are learning that COVID-19 impacts more than just the lungs. The list of potential issues multiplies when doctors also consider its impact on patients with other underlying conditions or the medications used to treat those conditions.
Dartmouth engineers have been awarded a $2.5 million grant from the National Cancer Institute, part of the National Institutes of Health, to develop and test a device--a microendoscopic electrical impedance sensing probe-- that could be used by surgeons to detect prostate cancer still left in the body during surgery.
A non-hormonal therapy to treat hot flashes and other symptoms associated with menopause was found to be effective in a recent clinical trial, according to a published study by a team of researchers including faculty from the University of Colorado School of Medicine.
Gender dysphoria manifests early in childhood and can persist for years before patients undergo counseling and treatment, a Cedars-Sinai study has found.
Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, announced today that results from a new study presented at the virtual 2020 meeting of the American Society of Clinical Oncology suggest that circulating tumor cell counts may be useful in determining long-term prognosis and guiding treatment selection in patients with metastatic castrate sensitive prostate cancer.
Up to now, women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face an unanswered question about whether surgery and radiation to the tumor in the breast (local therapy) will prolong survival compared to the traditional treatment of systemic treatment alone.
Breast cancer patients do not have an increased risk of developing rheumatoid arthritis. A Swedish cohort study has now come to this conclusion.
Researchers from the Harvard Medical School and Brigham and Women's Hospital working in collaboration have found that tofu and other plant-based proteins contain certain nutrients called isoflavones that can help those with heart disease and lower their disease risk.
Eric Prossnitz, PhD, hopes to help many of the 12% of American women who are projected to be diagnosed with breast cancer in their lifetimes.
In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.
Researchers from the Baylor College of Medicine and Harvard Medical School have found a novel mechanism to explain the resistance of certain breast cancers that spread in the major organs of the body. They hope that this would help develop new therapeutic strategies to treat the cancer.
Ductal carcinoma in-situ (DCIS) accounts for one-fifth of breast cancer cases in the United States, according to the American Cancer Society.
Researchers have managed to grow human, testosterone-producing cells, which could lead to improved treatment options for low testosterone levels.
October is Breast Cancer Awareness Month, an annual campaign to raise awareness about the potentially-fatal disease. Breast cancer is known as an illness that affects mostly women, but about 1 percent of all breast cancers affect men, too.